The ICC removed history of MDS or MDS/MPN as classifier for AML, and applies this history as a disease qualifier to the genetically-defined AML subtype; since most cases of AML progressed from MDS or MDS/MPN will have MR mutations and/or cytogenetic abnormalities, or fall into the TP53-mutated AML category in the ICC, these cases will still largely be in concordance with the AML-MR WHO-HAEM5 category. This evidence concerns the gene TP53 and intrahepatic cholangiocarcinoma.